NOTRELOAD AI
  • NOTRELOAD AI
  • Stocks BUZZ.
  • XYZ.
  • XY.
  • #TrumpTrade
  • Invest ↗
Sign in Subscribe

FDA Greenlights Linaclotide (Linzess) for Children 7 Years and Older with Irritable Bowel Syndrome with Constipation

Ironwood's Linzess is the first FDA-approved drug for children 7+ with IBS-C (chronic constipation, pain, and bloating).

FDA Greenlights Linaclotide (Linzess) for Children 7 Years and Older with Irritable Bowel Syndrome with Constipation
Photo by Supliful - Supplements On Demand on Unsplash
Already have an account? Sign in.
11/05/2025 · 11:40 AM
IRWD
/ Don't stop with just one post.

Related↓

Ironwood Rises as AbbVie’s Linzess Sales Beat Expectations
10/31/2025 · 4:53 PM

Ironwood Rises as AbbVie’s Linzess Sales Beat Expectations

Ironwood shares climb after AbbVie reports strong Q3 Linzess sales of $315M, surpassing estimates and boosting investor confidence.

/ Subscriber only
/ Read more

Feed↓

Axon Shares Plunge After Missing Q3 Profit Estimates Amid Tariff Pressures
11/05/2025 · 12:43 PM

Axon Shares Plunge After Missing Q3 Profit Estimates Amid Tariff Pressures

Axon Enterprise shares drop 10% after missing profit estimates due to rising tariff costs. The Taser-maker raises 2025 revenue outlook and announces a $625M Carbyne acquisition.

/ Subscriber only
Perrigo Rethinks Its Baby Formula Business
11/05/2025 · 11:59 AM

Perrigo Rethinks Its Baby Formula Business

Perrigo reviews its store-brand baby formula business due to quality issues. It is shifting focus to higher-profit health brands instead.

/ Subscriber only
Orexin Drug Race: Centessa Shows Promise, Alkermes Stands Strong
Featured/ 11/05/2025 · 10:28 AM

Orexin Drug Race: Centessa Shows Promise, Alkermes Stands Strong

Centessa has great sleep drug data, easing daytime sleepiness. Alkermes stock jumped 7% as its competing drug is still strong.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2025
Email address Subscribe